Oral Wegovy Management
Oral semaglutide is NOT currently FDA-approved for weight management—only subcutaneous Wegovy (semaglutide 2.4 mg weekly) is approved for obesity treatment. 1
Current FDA-Approved Wegovy Formulation
Subcutaneous Wegovy (semaglutide injection) is the only FDA-approved semaglutide formulation for weight management, indicated for adults and pediatric patients ≥12 years with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, and for cardiovascular risk reduction in adults with established CVD and obesity/overweight. 1
Dosing Schedule for Subcutaneous Wegovy
Start at 0.25 mg once weekly for 4 weeks, then escalate monthly:
- Weeks 1-4: 0.25 mg weekly
- Weeks 5-8: 0.5 mg weekly
- Weeks 9-12: 1 mg weekly
- Weeks 13-16: 1.7 mg weekly
- Week 17+: 2.4 mg weekly (recommended maintenance dose) or 1.7 mg weekly 1
Administration specifics:
- Inject subcutaneously in abdomen, thigh, or upper arm
- Same day each week, any time of day, with or without meals
- Monitor blood glucose in patients with type 2 diabetes before starting and during treatment 1
Oral Semaglutide Status
While oral semaglutide at 50 mg daily demonstrated 15.1% weight loss versus 2.4% with placebo at 68 weeks in clinical trials 2, it remains NOT FDA-approved for obesity treatment. The only FDA-approved oral semaglutide formulation is for type 2 diabetes at doses up to 14 mg daily 3.
Oral semaglutide 25 mg and 50 mg are investigational for weight management and showed promising results (13.6% and 17.1% weight loss respectively) 4, 5, but these formulations are not yet available for clinical use.
Essential Management Components
Medications must be combined with lifestyle interventions and used long-term 2:
- Reduced-calorie diet (typically -300 to -500 kcal/day)
- Physical activity: 150-200 minutes weekly minimum
- Behavioral counseling when available
Weight regain occurs rapidly after discontinuation—participants regained 6.9-11.6% of lost weight within 48-52 weeks of stopping 2, emphasizing the need for lifelong therapy.
Critical Safety Considerations
Absolute contraindications 1:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide
Common adverse effects (≥5%): nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue 1. Gastrointestinal symptoms are dose-dependent—gradual titration helps minimize these effects.
Serious warnings 1:
- Acute pancreatitis (discontinue if suspected)
- Acute gallbladder disease
- Hypoglycemia risk when combined with insulin or sulfonylureas (dose reduction required)
- Acute kidney injury (monitor renal function with severe GI reactions)
- Pulmonary aspiration risk during general anesthesia (inform surgeons/anesthesiologists of planned procedures)
- Suicidal ideation (monitor and discontinue if symptoms develop)
Cardiovascular Benefits
Semaglutide 2.4 mg reduces major adverse cardiovascular events by 20% (HR 0.80) in adults with established CVD and obesity/overweight without diabetes, driven by reductions in cardiovascular death, nonfatal MI, and nonfatal stroke 2. This represents a significant mortality and morbidity benefit beyond weight loss alone.
Clinical Pitfalls
Do not confuse formulations: Oral semaglutide for diabetes (Rybelsus, up to 14 mg daily) is NOT the same as investigational oral semaglutide for weight management (25-50 mg daily), and neither is approved for obesity treatment. Only subcutaneous Wegovy is FDA-approved for weight management.
Pregnancy: Discontinue at least 2 months before planned pregnancy due to long half-life (approximately 1 week) 1.
Drug interactions: Semaglutide delays gastric emptying—use caution with oral medications requiring rapid absorption or narrow therapeutic index 1.